Bill Ericson joined MDV in 2000 after more than a decade of working closely with entrepreneurs to start and build innovative businesses in the role of lawyer, board member, entrepreneur and investor. Bill believes that entrepreneurship is a singularity of the American experience, and strives to help as a key advisor and counselor to great entrepreneurs from the very earliest days of an enterprise.
Bill's investment focus at MDV is primarily in life sciences, with a current specific focus on molecular diagnostics and platforms that will enable the vision of personalized medicine. He works closely with a cross-disciplinary team of leading scientists, researchers and entrepreneurs, and seeks to apply technology solutions to life sciences in non-traditional ways. Bill has also led investments in a number of information technology and Internet companies.
Prior to MDV Bill founded and ran Venture Law Group's Seattle office. Bill is particularly proud of being a member of the founding team of Rosetta Inpharmatics and serving on its Board of Directors until its acquisition by Merck in 2001.
Bill serves on the Board of Northwestern University School of Law and is a member of the Personalized Medicine Coalition.
Bill received his B.S.F.S. from Georgetown University of Foreign Service and J.D. from Northwestern University School of Law.